Parsons SR, Rivas-Serna IM, Clandinin MT, Mazurak VC. Dietary eicosapentaenoic and docosahexaenoic acids decrease prostanoids in the ileum of rats treated with irinotecan and 5-fluorouracil. World J Gastrointest Oncol 2026; 18(9): 120472 [DOI: 10.4251/wjgo.120472]
Corresponding Author of This Article
Vera C Mazurak, PhD, Professor, Department of Agricultural, Food and Nutritional Science, University of Alberta, 4-002F Li Ka Shing Centre for Health Research, Edmonton T6G 2P5, Alberta, Canada. vmazurak@ualberta.ca
Research Domain of This Article
Oncology
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Parsons SR, Rivas-Serna IM, Clandinin MT, Mazurak VC. Dietary eicosapentaenoic and docosahexaenoic acids decrease prostanoids in the ileum of rats treated with irinotecan and 5-fluorouracil. World J Gastrointest Oncol 2026; 18(9): 120472 [DOI: 10.4251/wjgo.120472]
World J Gastrointest Oncol. Sep 15, 2026; 18(9): 120472 Published online Sep 15, 2026. doi: 10.4251/wjgo.120472
Dietary eicosapentaenoic and docosahexaenoic acids decrease prostanoids in the ileum of rats treated with irinotecan and 5-fluorouracil
Sarah R Parsons, Irma M Rivas-Serna, M Thomas Clandinin, Vera C Mazurak
Sarah R Parsons, Irma M Rivas-Serna, M Thomas Clandinin, Vera C Mazurak, Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton T6G 2P5, Alberta, Canada
M Thomas Clandinin, Department of Medicine, University of Alberta, Edmonton T6G 2P5, Alberta, Canada
Author contributions: Mazurak VC supervised the project; Parsons SR conducted analysis and drafted the manuscript; Rivas-Serna IM performed the fatty acid and oxylipin analysis; Clandinin MT supervised lipid analysis; Parsons SR, Clandinin MT, and Mazurak VC conceptualized the study, and interpreted, reviewed, and edited the draft; all authors reviewed and approved the final submission.
Supported by Canadian Institutes of Health Research, No. PS165820.
Institutional review board statement: This study does not involve any human experiments.
Institutional animal care and use committee statement: All animal use was approved by the University of Alberta Animal Care Committee and conducted in accordance with Guidelines of the Canadian Council on Animal Care (No. AUP00003572).
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: Dataset are available from the corresponding author (vmazurak@ualberta.ca) upon request.
Corresponding author: Vera C Mazurak, PhD, Professor, Department of Agricultural, Food and Nutritional Science, University of Alberta, 4-002F Li Ka Shing Centre for Health Research, Edmonton T6G 2P5, Alberta, Canada. vmazurak@ualberta.ca
Received: February 27, 2026 Revised: March 25, 2026 Accepted: July 28, 2026 Published online: September 15, 2026 Processing time: 179 Days and 22.3 Hours
Core Tip
Core Tip: The present study is the first to investigate n-6- and n-3-derived oxylipin levels from ileum tissue after irinotecan + 5-fluorouracil and modification by dietary eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The arachidonic acid (AA) metabolite 6-keto-prostaglandin F1α implicated in inhibiting water absorption and electrolyte dysregulation increased after irinotecan + 5-fluorouracil. Dietary EPA and DHA markedly reduced 6-keto-prostaglandin F1α and several other prostanoids while increasing protective and resolving mediators, lipoxin A4 (AA-derived) and protectin-D1 (DHA-derived). Oxylipin potential to reduce the risk of chemotherapy-induced adverse effects, such as diarrhea, should be explored in models of multi-cycle chemotherapy.
